A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious ...

Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s ...

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech said (PDF) Tuesday. The patient suffered acute ...

As part of its commitment to transparency, DMD published its 2024 Impact Report, detailing certified environmental performance, governance practices, and operational results aligned with SASB ...

This rare genetic disorder is due to the absence of a vital protein called dystrophin that helps the body maintain muscle cells, which results in rapid muscle degeneration and increasing muscle ...

Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...